Reviewer's report

Title: Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: Long term outcome of the Temporary Authorization for Use programme in France.

Version: 2  Date: 10 January 2015

Reviewer: Motoyoshi Tanaka

Reviewer's report:

Minor Essential Revisions

This MS demonstrated a recent topic modality to treat mCRPC after chemotherapy. Treatment for mCRPC has been changing dramatically in the decade from chemotherapy to molecular targeting to androgen. We can choose several modalities for mCRPC but do not know yet which agent or combination should be taken as a 1st line and how long and when to change. Indeed, treatment outcome for mCRPC has been certainly improving. Here are a few minor concerns regarding this MS, as below;

1. In the text of line 258-261, this part is explaining Fig. 2. Have difficulties deciphering the graph from the words. In Fig. 2, what do the dots represent? Need more clever explanations.

2. When treatment is discontinued with appropriate reasons, in general, further therapy might be applied except BSC. OS usually contains this bias. Furthermore, higher PS can accept longer adherence of medication or therapy, causing better survival benefit. Variables above should be involved and analyzed in the text and table 1.

Level of interest: An article of outstanding merit and interest in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.